Peloton Therapeutics Announces Completion of Enrollment in Phase 2 Trial of PT2977 for Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma

Peloton Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing first-in-class oral medicines for cancer and other serious conditions, announced the completion of patient enrollment in a Phase 2 clinical trial evaluating the efficacy and safety of its...

OSE Immunotherapeutics Announces Issuance of Canadian Patent and Notice of Allowance of U.S. Patent Protecting CD28-Antagonist Immunotherapy FR104

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) announces that it has strengthened its intellectual property rights for its Phase 2-ready product FR104, a monoclonal antibody antagonist of CD28, through the granting of a patent by the Canadian Intellectual...
SEARCH FOR STUDIES